Sentences with phrase «small molecule pharmaceuticals»

These large molecule drugs differ from traditional pharmaceuticals in that they are usually injected, while small molecule pharmaceuticals are taken in tablet form.

He has significant experience with respect to transactions related to small molecule pharmaceuticals, biologics, cellular therapies, gene therapy, diagnostics and medical devices, both within the United States as well as in other major markets such as Europe, Asia and South America.

Gill's expertise is in pharmaceutical chemistry, in particular drafting, prosecuting and defending small molecule pharmaceutical cases, primarily for pharmaceutical originators.

Not exact matches

SOUTH SAN FRANCISCO, Calif. — February 5, 2018 — FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small molecule drugs to activate the immune system against cancer, today announced the appointment of senior pharmaceutical research and development executive Michael F. Giordano, M.D., to its Board of Directors.

It is important to state that the Biotechnology industry does not include companies that are involved in developing small - molecule pharmaceuticals, performing contract research or manufacturing biological equipment.

There were two fresh names on the 2014 list: the largest U.S. pharma, Johnson & Johnson (J&J), which raked in $ 28 billion in worldwide pharmaceutical sales last year, reappeared at # 19 after a four - year absence, and a newcomer to the list Actelion (# 14), a Basel - based biotech currently working on 25 small molecules.

The researchers tested two anti-CK2 drugs for their ability to stimulate the production of new brown fat in mice: a new small - molecule CK2 - blocker called silmitasertib (CX - 4945), which is already in clinical trials as a cancer therapeutic; and a more precise next - generation antisense oligonucleotide (ASO) drug developed in collaboration with Isis Pharmaceuticals, which eliminates CK2 by blocking the RNA instructions cells use to produce it.

We have been fortunate to work in collaboration with the pharmaceutical company Pharmaxis, which is designing novel and highly selective small molecules that will allow the establishment of normal tissue architecture after wound repair.»

In September, Alnylam Pharmaceuticals announced that its small RNA molecules silenced the gene that causes the progressive disease hereditary ATTR amyloidosis in a successful phase III trial.

So the nascent pharmaceutical industry took a different tack, using a series of techniques to produce small - molecule drugs.

Yet one thing is clear: Major pharmaceutical manufacturers, originally skeptical about the prospects for large - molecule therapies, have long since joined the race to develop the treatments, acquiring, merging or partnering with small companies working on mAbs and other biologics.

Instead of using a set of genes to induce the cellular transformation, he relies primarily on pharmaceutical compounds, known as «small molecules.»

The overarching trend right now in bioprocessing and pharmaceuticals is essentially the shift from small molecules and biologics to now cell and gene therapies.

Accurate modeling of how small molecules bind to GPCRs could contribute to development of new pharmaceuticals.

«The idea of using a small molecule, like auxin, to rescue a protein - protein interaction is new in the pharmaceutical industry,» says Zheng.

In another sign of growing pharmaceutical industry interest in targeted protein degradation, Celgene will pay Vividion Therapeutics $ 101 million in a four - year pact to develop small - molecule drugs for cancer, inflammation, and neurodegenerative diseases.

Other companies, including the Swiss drug giants Novartis and Roche, along with Boston's Paratek Pharmaceuticals, are developing ingestible small - molecule drugs designed to increase the inclusion of SMN2 «s exon 7.

Researchers from all over the world are challenged to predict how small molecules, such as pharmaceuticals, bind to GPCRs at the atomic level.

In fact, Liu notes that pharmaceutical companies are trying to develop small molecule HIF inhibitors as cancer treatment.

ORIC Pharmaceuticals, Inc. is a small molecule oncology company focused on combating the growing resistance problem to current molecularly targeted drugs.

The mixed phosphonates are prevalent in pharmaceuticals and bioactive small molecules such as antibacterial, ligand prodrug, and enzyme inhibitors.

Rigel Pharmaceuticals, Inc is a clinical - stage drug development company that discovers and develops novel, small - molecule drugs for the treatment of inflammatory / autoimmune diseases, as well as for certain cancers and metabolic diseases.

Its pharmaceutical products include chemically - synthesized drugs or small molecules and an increasing portion of products produced from biological processes called biologics.

ACADIA Pharmaceuticals Inc. is focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Vertex Pharmaceuticals is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.

We speak to Lisa Mueller, an expert in protecting unique small molecules, biologics and DNA and protein sequences that are critical to the pharmaceutical and biotechnology industries.

Our clients range from medical device and pharmaceutical manufacturers to companies focusing on diagnostic testing, biologics, biosimilars and small molecules, among other areas of the life sciences industry.

Typically, companies in the pharmaceutical and biotechnology industries file patents protecting small molecules, biologics (an antibody, peptide sequence, etc), methods of treatment or unique (diagnostic) assays (for detecting and / or treating disease).

Works with start - up company to navigate a complex small molecule patent landscape and develop an exclusivity proposition attractive to large pharmaceutical partners.

Performed pro-bono work investigating small cap pharmaceutical companies, ensuring scientific and clinical relevance for target drugs, revenue forecasting, market research for drugs with similar target molecule

Senior manager and director of pharmaceutical process chemistry, manufacturing and controls (CMC) specializing in cGMP, quality and regulatory compliance of novel small and large molecule therapeutic drugs including peptides, nucleotides, protein biologics and antibody drug conjugates (ADCs).

CAREER SUMMARY * Senior, seasoned pharmaceutical R&D professional with strong administrative, strategic & scientific planning, and coordination / execution skills, gained through 27 years of industrial experience in leading CMC technical development function (Pharmaceutics & Analytical), and leading global development & regulatory filings for NMEs (small molecule and biologics / mAb), and 505 (b)(2) products strong expertise...